Platelet lysates promote mesenchymal stem cell expansion: A safety substitute for animal serum in cell-based therapy applications
Platelet lysates promote mesenchymal stem cell expansion: A safety substitute for animal serum in cell-based therapy applications
复制标题
DOI：
10.1002/jcp.20391
复制
发表时间：
2005-11-01
影响因子：
5.6
通讯作者：
Lataillade, JJ
中科院分区：
文献类型：
--
作者：
Doucet, C;Ernou, I;Lataillade, JJ
间充质干细胞（MSCs）被认为是一种新兴的“通用”细胞，各种使用MSCs的组织修复计划正在开发中。MSCs的体外扩增通常在含有胎牛血清（FCS）的培养基中实现，并通过添加生长因子来增加。然而，为了广泛的临床应用，必须尽量减少MSCs与FCS的接触，因为它被认为是朊病毒或病毒传播的来源。因此，由于血小板是生长因子的天然来源，我们试图研究从富血小板血浆中获得的血小板裂解物（PL）对体外MSC扩增的反应。人间充质干细胞在添加FCS （+/- bFGF）或pl的培养基中通过传代培养过程进行扩增。我们证明了含有PL的培养基富含生长因子（血小板衍生生长因子（PDGFs），碱性成纤维细胞生长因子（bFGF），转化生长因子tgf - β），胰岛素样生长因子-1 （IGF-1）…)，并表明与FCS培养基相比，PL能够促进MSC扩增，减少达到融合所需的时间，并增加CFU-F大小。此外，我们证明了在PL存在下培养的MSCs保持其成骨、软骨和脂肪分化特性，并保持其免疫抑制活性。因此，我们建议在临床环境中使用MSCs开发组织和细胞工程产品时，PL可能是FCS的一种强大而安全的替代品。
Mesenchymal stem cells (MSCs) are considered as emergent "universal" cells and various tissue repair programs using MSCs are in development. In vitro expansion of MSCs is conventionally achieved in medium containing fetal calf serum (FCS) and is increased by addition of growth factors. However, for widespread clinical applications, contact of MSCs with FCS must be minimized since it is a putative source of prion or virus transmission. Therefore, because platelets are a natural source of growth factors, we sought to investigate in vitro MSC expansion in response to platelet lysates (PL) obtained from platelet-rich plasma. Human MSCs were expanded in FCS (+/- bFGF)- or PL-supplemented medium through a process of subculture. We demonstrated that PL-containing medium is enriched by growth factors (platelet-derived growth factors (PDGFs), basic fibroblast growth factor (bFGF), transforming growth factor TGF-beta), insulin-like growth factor-1 (IGF-1)...) and showed that PL is able to promote MSC expansion, to decrease the time required to reach confluence, and to increase CFU-F size, as compared to the FCS medium. Furthermore, we demonstrated that MSCs cultured in the presence of PL maintain their osteogenic, chondrogenic, and adipogenic differentiation properties and retain their immunosuppressive activity. Therefore, we propose that PL may be a powerful and safe substitute for FCS in development of tissue- and cellular-engineered products in clinical settings using MSCs.